Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 8/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19012507 | 0.81 | PDK1 (0.36) | PDK1PDK2PARP1TNKSTNKS2 | |
| SCHEMBL19012509 | 0.74 | PARP1 (0.35) | PDK1PDK2PARP1TNKSTNKS2 | |
| SCHEMBL15492374 | 0.74 | PARP1 (0.44) | PDK1PDK2PARP1TNKSTNKS2 | |
| SCHEMBL19058891 | 0.73 | PARP1 (0.44) | PDK1PDK2PARP1TNKSTNKS2 | |
| SCHEMBL5935898 | 0.72 | PDK1 (0.45) | PDK1PDK2PARP1TNKSTNKS2 | |
| SCHEMBL3868872 | 0.68 | — | — | |
| SCHEMBL8171386 | 0.67 | DPP4 (0.43) | DPP4DPP9DPP8DPP7P2RX7 | |
| SCHEMBL4431123 | 0.67 | HTR2C (0.30) | — | |
| SCHEMBL22506639 | 0.64 | PDK1 (0.60) | PDK1PDK2 | |
| SCHEMBL22506640 | 0.64 | PDK1 (0.60) | PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | PDK1 1315/4885PDK2 1509/4885PARP1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.